Mar 17, 2022 / 06:40PM GMT
Daniel Thengone - Oppenheimer & Co. Inc. - Analyst
All right. Hello, everyone. Welcome to day three of our Oppenheimer Healthcare Conference and thanks for joining us today. My name is Daniel [Thengone], I am a biotech research associate here at Oppenheimer. And it's my pleasure to introduce iBio. iBio is a plant-based biopharmaceutical company that is leveraging its FastPharming technologies to develop novel biopharmaceuticals in oncology, fibrotic diseases and infectious diseases.
From the company, we have CEO and Chairman, Tom Isett, to present. In terms of the format here, we'll have the company present for about 20, 25 minutes, followed by some time for Q&A. Please feel free to send over questions using the Q&A chat at the bottom of your screen, and I'll do my best to get to all of them.
With that, thank you very much, Tom, for joining us today, and please take it away.
Tom Isett - iBio, Inc. - CEO & Chairman of the Board
Great. Thanks, Daniel, and happy Thursday to you and everybody. Thanks for joining. We're going to be,
Ibio Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers